PLK1/BRD4-IN-1

PLK1/BRD4-IN-1 (9b) is a potent, orally bioavailable dual inhibitor targeting PLK1 and BRD4 with IC50 values of 22 nM and 109 nM, respectively. It demonstrates significant anti-tumor activity in vivo, making it a valuable chemical probe for oncology research, particularly in studying cell cycle progression and epigenetic regulation in cancer models.